

Landry, Baton Rouge, Louisiana; to collectively retain 16.60 percent of the outstanding voting shares of West Baton Rouge Bancshares, Inc., and its subsidiary, Bank of West Baton Rouge, both of Port Allen, Louisiana.

B. Federal Reserve Bank of

Minneapolis (JoAnne F. Lewellen, Assistant Vice President) 90 Hennepin Avenue, Minneapolis, Minnesota 55480-0291:

1. *Robert L. Frei*, Wagner, South Dakota; to acquire voting shares of Commercial Holding Company, Wagner, South Dakota, and thereby indirectly acquire voting shares of Commercial State Bank of Wagner, Wagner, South Dakota.

Board of Governors of the Federal Reserve System, August 20, 2001.

Jennifer J. Johnson,

Secretary of the Board.

[FR Doc. 01-21459 Filed 8-23-01; 8:45 am]

BILLING CODE 6210-01-S

FEDERAL RESERVE SYSTEM

Formations of, Acquisitions by, and Mergers of Bank Holding Companies

The companies listed in this notice have applied to the Board for approval, pursuant to the Bank Holding Company Act of 1956 (12 U.S.C. 1841 *et seq.*) (BHC Act), Regulation Y (12 CFR Part 225), and all other applicable statutes and regulations to become a bank holding company and/or to acquire the assets or the ownership of, control of, or the power to vote shares of a bank or bank holding company and all of the banks and nonbanking companies owned by the bank holding company, including the companies listed below.

The applications listed below, as well as other related filings required by the Board, are available for immediate inspection at the Federal Reserve Bank indicated. The application also will be available for inspection at the offices of the Board of Governors. Interested persons may express their views in writing on the standards enumerated in the BHC Act (12 U.S.C. 1842(c)). If the proposal also involves the acquisition of a nonbanking company, the review also includes whether the acquisition of the nonbanking company complies with the standards in section 4 of the BHC Act (12 U.S.C. 1843). Unless otherwise noted, nonbanking activities will be conducted throughout the United States. Additional information on all bank holding companies may be obtained from the National Information Center website at www.ffiec.gov/nic/.

Unless otherwise noted, comments regarding each of these applications

must be received at the Reserve Bank indicated or the offices of the Board of Governors not later than September 18, 2001.

A. Federal Reserve Bank of Richmond (A. Linwood Gill, III, Vice President) 701 East Byrd Street, Richmond, Virginia 23261-4528:

1. *FNB Corporation*, Christiansburg, Virginia; to acquire 100 percent of the voting shares of FNB Southwest, National Association, Roanoke, Virginia (successor by charter conversion to Southwest Virginia Savings Bank, FSB, Roanoke, Virginia).

B. Federal Reserve Bank of Dallas (W. Arthur Tribble, Vice President) 2200 North Pearl Street, Dallas, Texas 75201-2272:

1. *International Bancshares Corporation*, Laredo, Texas, and IBC Subsidiary Corporation, Wilmington, Delaware; to acquire 100 percent of the voting shares of National Bancshares Corporation of Texas, San Antonio, Texas; and thereby indirectly acquire NBT of Delaware, Inc., Wilmington, Delaware; and NBC Bank, National Association, Eagle Pass, Texas.

Board of Governors of the Federal Reserve System, August 20, 2001.

Jennifer J. Johnson,

Secretary of the Board.

[FR Doc. 01-21460 Filed 8-23-01; 8:45 am]

BILLING CODE 6210-01-S

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP): Program Announcement (PA) #01187, Counseling & Testing in Emergency Room & Ambulatory Care; PA #01188, Social & Environmental Interventions To Prevent HIV, and PA #01191, Efficacy of Condom Skills Building Demonstrations

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92-463), the Centers for Disease Control and Prevention (CDC) announces the following meeting.

Name: Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP): PA #01187, Counseling & Testing in Emergency Room & Ambulatory Care; PA #01188, Social & Environmental Interventions to Prevent HIV; and PA #01191, Efficacy of Condom Skills Building Demonstrations, meeting.

Times and Date: 8 a.m.-9 a.m., September 11, 2001 (Open); 9 a.m.-5 p.m., September

11, 2001 (Closed); 8 a.m.-5 p.m., September 12, 2001 (Closed).

Place: The Double Tree Hotel Atlanta Buckhead, 3342 Peachtree Road, NE, Atlanta, Georgia 30326.

Status: Portions of the meeting will be closed to the public in accordance with provisions set forth in section 552b(c)(4) and (6), Title 5 U.S.C., and the Determination of the Deputy Director for Program Management, CDC, pursuant to Public Law 92-463.

Matters To Be Discussed: The meeting will include the review, discussion, and evaluation of applications received in response to Program Announcements 01187, 01188, and 01191.

For Further Information Contact: Beth Wolfe, Prevention Support Office, National Center for HIV, STD, and TB Prevention, CDC, Corporate Square Office Park, 8 Corporate Square Boulevard, M/S E07, Atlanta, Georgia 30329, telephone 404/639-8025.

The Director, Management Analysis and Services office has been delegated the authority to sign Federal Register notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.

Dated: August 20, 2001.

Carolyn J. Russell,

Director, Management Analysis and Services Office, Centers for Disease Control and Prevention CDC.

[FR Doc. 01-21403 Filed 8-23-01; 8:45 am]

BILLING CODE 4163-18-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

Blood Products Advisory Committee; Notice of Meeting

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

This notice announces a forthcoming meeting of a public advisory committee of the Food and Drug Administration (FDA). The meeting will be open to the public.

Name of Committee: Blood Products Advisory Committee.

General Function of the Committee:

To provide advice and recommendations to the agency on FDA's regulatory issues.

Date and Time: The meeting will be held on September 20, 2001, from 8 a.m. to 5 p.m., and on September 21, 2001, from 8 a.m. to 3:30 p.m.

Location: Hilton DC North—Gaithersburg, 620 Perry Pkwy., Gaithersburg, MD.

Contact: Linda A. Smallwood, Center for Biologics Evaluation and Research